Deep Track Capital Portfolio
13F Holdings & Position Changes — Last filed May 15, 2026
13F Holdings & Position Changes — Last filed May 15, 2026
Greenwich-based life sciences investment advisor founded by David Kroin, who previously co-founded Great Point Partners. Invests across public and private biotech, pharmaceutical, and medical device companies with over 25 years of healthcare investment expertise driving concentrated, high-conviction positioning.
Deep Track Capital is a $5B biotech-focused hedge fund managed by David Kroin. As of their latest 13F filing (Q1 2026), the fund holds 61 positions worth $4.8B. This quarter they initiated 9 new positions and exited 89. Their largest holding is GH ($308.4M).
Deep initiated 9 new positions and increased 30 this quarter. Portfolio grew +18.7% to $4.8B. 584 upcoming catalysts across holdings.
Portfolio Value (13F)
$4.8B
Holdings
61
Top 10 Concentration
44.7%
QoQ Change
+18.7%
Turnover
9.0%
Portfolio Value Trend
Be first to know when Deep Track Capital files next quarter
Get an email the moment new buys, exits, and conviction changes hit. Free 14-day trial.
| # | Ticker | Company | Change | Value | % of Portfolio | SI % Float ? | Trend |
|---|---|---|---|---|---|---|---|
| 1 | GH | Guardant Health Inc. | Increased | $308.4M | 6.40% | 10.4% | |
| 2 | IMVT | Immunovant Inc. | $286.3M | 5.94% | 21.2% | ||
| 3 | TARS | Tarsus Pharmaceuticals Inc. | Increased↑5Q | $252.5M | 5.24% | 12.0% | |
| 4 | PCVX | Vaxcyte Inc. | Increased↑5Q | $249.9M | 5.19% | 10.1% | |
| 5 | GPCR | Structure Therapeutics Inc. | Increased | $206.3M | 4.28% | 11.4% | |
| 6 | AXSM | Axsome Therapeutics Inc. | Decreased | $185.9M | 3.86% | 10.0% | |
| 7 | APLS | Apellis Pharmaceuticals Inc. | Decreased↓2Q | $182.3M | 3.78% | 12.6% | |
| 8 | OCUL | Ocular Therapeutix Inc. | Increased | $166.7M | 3.46% | 14.3% | |
| 9 | VERA | Vera Therapeutics Inc. | Increased↑2Q | $165.2M | 3.43% | 18.8% | |
| 10 | ALMS | Alumis Inc. | New | $149.2M | 3.10% | 15.4% | — |
Share changes reflect active decisions. Value changes include price moves.
Track this fund’s next move
13F changes, conviction shifts, and catalyst alerts across all 20 specialist biotech funds — free Monday brief.
See all 61 holdings (you're viewing the top 10), plus 9 quarters of position history.
No charge for 14 days · Cancel anytime
Deep Track Capital held 61 biotech stocks in their 13F portfolio this quarter. Their top positions include GH, IMVT, TARS, PCVX, GPCR. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
Deep Track Capital's tracked biotech portfolio is worth $4.8B across 61 positions, with total assets under management of approximately $5B. Portfolio values are based on 13F filings with the SEC.
Deep Track Capital initiated 9 new positions this quarter, including ALMS, GNMSF, DFTX, CRVS, MANE and 4 more. They also increased 30 existing positions.
Deep Track Capital fully exited 89 positions this quarter, including HRMY, NVAX, SRPT, SEPN, SYRE and 84 more. They also trimmed 13 existing positions.
Greenwich-based life sciences investment advisor founded by David Kroin, who previously co-founded Great Point Partners. Invests across public and private biotech, pharmaceutical, and medical device companies with over 25 years of healthcare investment expertise driving concentrated, high-conviction positioning.
Track specialist biotech funds, insider signals, and AI analysis
Start 14-Day Free Trial